More importantly, it has recently been demonstrated that ovarian cancer-derived EVs can drive T cell exhaustion in the tumor microenvironment through SK1/S1P-mediated signaling and impacting immunotherapy outcomes [34]. This evidence concerns the gene SPHK1 and ovarian cancer.